Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma

Ghobrial, Irène M.; Dispenzieri, Angela; Bundy, Kevin L.; Gastineau, Dennis A.; Rajkumar, S. Vincent; Therneau, Terry M.; Lacy, Martha Q.; Witzig, Thomas E.; Litzow, Mark R.; Christensen, Bryce; Hayman, S. R.; Pribula, C. G.; Gertz, Morie A.

doi:10.1038/sj.bmt.1704173

Cited by 31 publications

(29 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been confirmed by many study groups that THAL as a single agent (Dmoszynska et al, 2000;Patriarca et al, 2003) or combined with VAD (Ahmad et al, 2002;Pitini et al, 2003) could be a suitable bridging regimen to PBSC collection and autologous SCT for VAD-refractory MM patients. Moreover, Ghobrial et al (2003) showed that THAL does not substantionally affect peripheral blood mobilisation or engraftment, which is in line with our observation. For patients with low pretreatment level, other therapeutical options, such as a combination of THAL with chemotherapy or bortezomid, should be considered since such options can significantly increase the response rate.…”

Section: Discussionsupporting

confidence: 92%

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

et al. 2004

View full text Add to dashboard Cite

The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months. The study was carried out on 234 patients who received THAL for relapsed/refractory myeloma. Out of the 234 patients, 129 patients (55.1%) responded to THAL with a mean response duration of 11.9 months (ranging from 1 to 48) and an overall survival rate of 20.3 months (ranging 1 -55 months). In 64 patients (27.4% of the whole group), the response to THAL lasted X18 months with a mean response lasting 24 months. Statistical analysis of the group of nonresponders and patients with long-term response to THAL showed a significantly higher serum albumin level (P ¼ 0.0003) and haemoglobin level (P ¼ 0.05), as well as a lower b2 microglobulin (b2M) (P ¼ 0.022), LDH (P ¼ 0.045) serum level in patients with long-term response. In this study, the LDH and serum albumin level were predictors for response to THAL therapy. The b2M serum level was not a predictor for response to THAL. The albumin serum level was the best parameter distinguishing the group of patients with long-term response to THAL from the entire responding group (P ¼ 0.02).

show abstract

Section: Discussionsupporting

confidence: 92%

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

et al. 2004

View full text Add to dashboard Cite

show abstract

“…[28][29][30] In a recent study, 31 early platelet engraftment of 20 000/ml was affected by previous thalidomide use. In line with other studies, we found on univariate analysis that the platelet engraftment (420 000/ml) was affected by the number of CD34 cells infused.…”

Section: Discussionmentioning

confidence: 99%

First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma

Abdelkefi¹,

Torjman²,

Romdhane

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Thalidomide-dexamethasone therapy was given in patients (o61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line therapy, thalidomide and dexamethasone were administered for 75 days (200 mg/day) and 3 months, respectively. The monthly dose of dexamethasone was 20 mg/m 2 /day for 4 days, with cycles repeated on days 9 to 12 and 17 to 20 on the first and the third month of therapy. After first-line therapy, a collection of peripheral blood stem cells (PBSC) was performed. Between May 2003 and September 2004, 60 patients were included. On an intent-to-treat basis, the overall response (Xpartial response) rate was 74%, including 24% of patients who obtained a complete remission. Grade 3-4 toxicities consisted of infections (12%), deep-vein thrombosis (3%), constipation (5%), and neuropathy (5%). A total of 58 patients (96%) proceeded to PBSC mobilisation and yielded a median number of 8 Â 10 6 CD34 þ cells/kg. First-line thalidomide-dexamethasone therapy is effective and relatively well tolerated in young patients with symptomatic multiple myeloma. This combination does not affect PBSC mobilisation.

show abstract

“…Regarding the impact of the initial treatment on engraftment post ASCT, controversial results have been published. 2,3 In our study, a delayed engraftment in patients previously treated with Thal-Dex was observed.…”

mentioning

confidence: 77%

Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma

Oksman

Itälä‐Remes

Kauppila

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Several factors have been found to affect engraftment after autologous SCT (ASCT) in multiple myeloma (MM), including source of stem cells, number of infused CD34+ cells, prior use of myelotoxic agents and use of haematopoietic growth factors post ASCT. Recently, bisphosphonates were shown to delay haematological recovery after ASCT in mice when compared to untreated controls. 1 To the best of our knowledge, this has not been studied in the clinical setting. The aim of this study was to evaluate the impact of bisphosphonates on haematological recovery after ASCT in patients with MM. We analysed 207 myeloma patients transplanted in

show abstract

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma

Cited by 31 publications

References 29 publications

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma

Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma

Contact Info

Product

Resources

About